Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal

Felicita Andreotti, Filippo Crea, Mattia Galli, Domenico D'Amario, Rocco Antonio Montone, Giampaolo Niccoli

Risultato della ricerca: Contributo in rivistaArticolo in rivista

3 Citazioni (Scopus)

Abstract

•The optimal antithrombotic regimen to be used in patients with AF and PCI or ACS is still debated.•Each of the six randomised controlled trials comparing double to triple therapy has limitations.•None was powered to assess differences between treatment arms in ischaemic event rates.•The contrasting results regarding ischaemic events within published meta-analyses can be explained by heterogeneity, incompleteness and varying definitions of stent thrombosis.•The overall reduced bleeding rates, but increased early definite and probable stent thrombosis rates with double versus triple antithrombotic therapy encourage consideration of triple therapy during the first weeks from PCI followed by double therapy.
Lingua originaleEnglish
pagine (da-a)100524-N/A
RivistaINTERNATIONAL JOURNAL OF CARDIOLOGY. HEART & VASCULATURE
Volume28
DOI
Stato di pubblicazionePubblicato - 2020

Keywords

  • Acute coronary syndrome
  • Anticoagulant
  • Antiplatelet
  • Antithrombotic
  • Atrial fibrillation
  • Double
  • Percutaneous coronary intervention
  • Triple

Fingerprint

Entra nei temi di ricerca di 'Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal'. Insieme formano una fingerprint unica.

Cita questo